2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis

Other illness

• Any medical or psychological condition in the treating physician's opinion which may prevent the patient from study participation for the 2 year study period.\*
• Patients participated in an interventional clinical trial with secukinumab involvement in the past.
  • Note: For example, patients diagnosed with a terminal illness and those with cognitive impairment due to dementia and Alzheimer's disease.

Other

• Patients participating in parallel in other interventional clinical trial.

• Written informed consent of the patient to participate in the study
• Age 18-80 years.
• Patients with an assured diagnosis by the treating physician of active moderate to severe plaque psoriasis or active PsA or active AS or active non-radiographic axial SpA.
• Patients must have received the official approval to receive secukinumab in Dermatology Disease Prior Authorization (DDPA) or Rheumatology Disease Prior Authorization (RDPA) before study participation or the decision to treat patient's condition with secukinumab is happened before entering the study
• Patients must receive the first dose of secukinumab during the study enrollment period.
• Patients for whom the decision for a therapy with secukinumab is made by the attending treating physician, regardless of this non-interventional study.
• Patients who have EQ-5D score before start the 1st dose secukinumab.